| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Ashraf T Soliman | |
| Heba Elsedfy | |||
| Vincenzo De Sanctis | |||
| Salvatore Di Maio | |||
| Nada Soliman | |||
| P2860 | cites work | Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density | Q24247748 |
| Long-term effects of gonadotropin-releasing hormone analogs in girls with central precocious puberty | Q26851792 | ||
| Challenges and controversies in diagnosis and management of gonadotropin dependent precocious puberty: An Indian perspective | Q28085099 | ||
| Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics | Q28145227 | ||
| Age of menarche and near adult height after long-term gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty | Q33726991 | ||
| The epidemiology and demographics of slipped capital femoral epiphysis | Q33776350 | ||
| Side effects of GnRH analogue treatment in childhood | Q34021744 | ||
| Relation of early menarche to depression, eating disorders, substance abuse, and comorbid psychopathology among adolescent girls | Q34090907 | ||
| Clinical longitudinal standards for height and height velocity for North American children | Q34193043 | ||
| Can GnRH-agonist treatment cause slipped capital femoral epiphysis? | Q34308630 | ||
| The prevalence and features of the polycystic ovary syndrome in an unselected population | Q34325018 | ||
| Outcomes of early pubertal timing in young women: a prospective population-based study | Q34353224 | ||
| Slipped capital femoral epiphyses associated with the withdrawal of a gonadotrophin releasing hormone | Q34369821 | ||
| Slipped capital femoral epiphysis during the treatment of precocious puberty with a gonadotropin-releasing hormone-agonist: aetiological considerations | Q34375694 | ||
| Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty | Q34398239 | ||
| Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. | Q34423618 | ||
| Final height in central precocious puberty after long term treatment with a slow release GnRH agonist | Q34799921 | ||
| Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years | Q35264882 | ||
| Elevated social anxiety among early maturing girls. | Q35827468 | ||
| Recurrent anaphylaxis associated with gonadotropin-releasing hormone analogs: case report and review of the literature. | Q36662921 | ||
| Clinical review: Identifying children at risk for polycystic ovary syndrome | Q36688099 | ||
| Precocious puberty in girls | Q36701023 | ||
| Pseudotumour Cerebri Presentation in a Child Under the Gonadotropin-Releasing Hormone Agonist Treatment | Q37395164 | ||
| Early puberty, negative peer influence, and problem behaviors in adolescent girls | Q37421122 | ||
| Consensus statement on the use of gonadotropin-releasing hormone analogs in children | Q37427053 | ||
| Treatment and outcomes of precocious puberty: an update | Q38091621 | ||
| Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects | Q38124612 | ||
| Pubertal timing in girls and depression: a systematic review | Q38166070 | ||
| Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty | Q38203526 | ||
| New causes of central precocious puberty: the role of genetic factors. | Q38239266 | ||
| Pediatric pseudotumor cerebri: descriptive epidemiology. | Q41580146 | ||
| Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty | Q41975684 | ||
| Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy | Q42166162 | ||
| Efficacy of a monthly compared to 3-monthly depot GnRH analogue (goserelin) in the treatment of children with central precocious puberty | Q42170848 | ||
| Insulin sensitivity and lipid profiles in girls with central precocious puberty before and during gonadal suppression | Q43059515 | ||
| Hypersensitivity vasculitis associated with leuprolide (Lupron). | Q43063254 | ||
| Sterile abscess formation associated with depot leuprorelin acetate therapy for central precocious puberty | Q44125992 | ||
| Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). | Q44126974 | ||
| Occurrence of slipped capital femoral epiphysis in children undergoing gonadotropin-releasing hormone agonist therapy for the treatment of central precocious puberty | Q44959780 | ||
| Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results | Q46080487 | ||
| Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years | Q46147534 | ||
| Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty. | Q46296112 | ||
| Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study | Q46299275 | ||
| Two-year results of treatment with depot leuprolide acetate for central precocious puberty | Q46910376 | ||
| Luteinizing hormone releasing hormone analogue therapy for central precocious puberty. Long-term effect on somatic growth, bone maturation, and predicted height | Q47208551 | ||
| Factors influencing final/near-final height in 12 boys with central precocious puberty treated with gonadotrophin-releasing hormone agonists. Italian Study Group of Physiopathology of Puberty | Q47230453 | ||
| Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized long-term pilot study | Q47255602 | ||
| Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty | Q47260380 | ||
| Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty | Q47263045 | ||
| Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function | Q47265579 | ||
| Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards | Q47446269 | ||
| Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty | Q47672857 | ||
| Early menarche predicts increased depressive symptoms and cortisol levels in Quebec girls ages 11 to 13. | Q48400908 | ||
| Effects and safety of combination therapy with gonadotropin-releasing hormone analogue and growth hormone in girls with idiopathic central precocious puberty: a meta-analysis | Q50207823 | ||
| The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty. | Q53379250 | ||
| Central Precocious Puberty: Update on Diagnosis and Treatment. | Q54943308 | ||
| Gonadotropin-releasing hormone analog therapeutics | Q57149519 | ||
| Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment | Q57223906 | ||
| Menstrual cycle pattern during the first gynaecological years in girls with precocious puberty following gonadotropin-releasing hormone analogue treatment | Q58493494 | ||
| Is a Combination of a GnRH Agonist and Recombinant Growth Hormone an Effective Treatment to Increase the Final Adult Height of Girls with Precocious or Early Puberty? | Q61453758 | ||
| Transient Arterial Hypertension Induced by Gonadotropin-Releasing Hormone Agonist Treatment for Central Precocious Puberty | Q64075564 | ||
| Preventability and severity assessment in reporting adverse drug reactions | Q68043455 | ||
| The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy | Q70276135 | ||
| Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty | Q70748980 | ||
| Local reactions to depot leuprolide therapy for central precocious puberty | Q72866628 | ||
| Central precocious puberty: From genetics to treatment | Q73794176 | ||
| Prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist | Q74433265 | ||
| The effect of ovariectomy and oestrogen replacement on small artery biomechanics in the rat | Q78061447 | ||
| Gonadotropin-releasing hormone analog therapy for central precocious puberty and other childhood disorders affecting growth and puberty | Q79141738 | ||
| Familial central precocious puberty suggests autosomal dominant inheritance | Q79891189 | ||
| Anaphylaxis to leuprolide acetate depot injection during treatment for prostate cancer | Q80439601 | ||
| Anaphylactic reaction to different gonadotropin-releasing hormone agonists for the treatment of endometriosis | Q83202582 | ||
| Insight: prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist: a proposed mechanism and management plan | Q84841371 | ||
| Hypertension during therapy with triptorelin in a girl with precocious puberty | Q85527160 | ||
| Arterial hypertension during treatment with triptorelin in a child with Williams-Beuren syndrome | Q87412499 | ||
| Toward More Targeted and Cost-Effective Gonadotropin-Releasing Hormone Analog Treatment in Girls with Central Precocious Puberty | Q90507686 | ||
| Does the risk of arterial hypertension increase in the course of triptorelin treatment? | Q90852042 | ||
| The global incidence and prevalence of anaphylaxis in children in the general population: A systematic review | Q91246969 | ||
| Update on central precocious puberty: from etiologies to outcomes | Q91580496 | ||
| Leuprolide acetate-induced generalized papular eruption | Q95406163 | ||
| P433 | issue | 3 | |
| P921 | main subject | precocious puberty | Q224513 |
| P304 | page(s) | 345-359 | |
| P577 | publication date | 2019-09-06 | |
| P1433 | published in | Acta Biomedica de l'Ateneo Parmense | Q15765294 |
| P1476 | title | Long-term effects and significant Adverse Drug Reactions (ADRs) associated with the use of Gonadotropin-Releasing Hormone analogs (GnRHa) for central precocious puberty: a brief review of literature | |
| P478 | volume | 90 |
Search more.